Ectodermal Dysplasia (ED) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Ectodermal dysplasias (ED) are a group of more than 180 disorders that affect the outer layer of tissue of the embryo (ectoderm) that helps make up the skin, sweat glands, hair, teeth, and nails.
Etiology-
Mutations in EDA, EDAR, EDARADD, and WNT10A. EDA genes are
the most common cause of the disorder, accounting for more than half of all
cases.
Epidemiology-
Hypohidrotic ectodermal
dysplasia is the most common form of ectodermal dysplasia. It is estimated to
occur in 1 in 20,000 newborns worldwide.
The competitive
landscape of Ectodermal Dysplasia (ED) includes country-specific approved as
well as pipeline therapies. Any asset/product-specific designation or review
and Accelerated Approval are being tracked and supplemented with analyst
commentary.
KOLs insights of Ectodermal Dysplasia (ED)
across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated
in the study. Insights around current treatment landscape, epidemiology,
clinical characteristics, future treatment paradigm, and Unmet needs.
Ectodermal
Dysplasia (ED) Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 EDI200 Edimer
Pharmaceuticals Phase 2
2 PTX-022 Palvella
Therapeutics, Inc. Phase 3
3 1% sirolimus cream TransDerm,
Inc. Phase
1
Comments
Post a Comment